Vistagen announces topline results from palisade-1 phase 3 clinical trial for investigational drug ph94b

South san francisco, calif.--(business wire)--vistagen therapeutics, inc. (nasdaq: vtgn) (vistagen, the company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced topline results from its palisade-1 phase 3 clinical trial of ph94b for the acute treatment of anxiety in adults with social anxiety disorder. ph94b did not achieve its primary e
VTGN Ratings Summary
VTGN Quant Ranking